How do I buy Royalty Pharma (RPRX) stock?

Buying Royalty Pharma (RPRX) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and verify your identity. Make a deposit. Search for the code "RPRX", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy RPRX by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

How do I tell if RPRX is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Royalty Pharma (RPRX) Stock

Q: What is the minimum investment for RPRX on Gotrade?

On Gotrade , you don't have to buy a full share. With fractional shares, you can start investing in Royalty Pharma from just $1. A small budget shouldn't stop you from building a US stock portfolio.

NASDAQ · RPRX

Trade RPRX

Key stats

Market cap: $31.17B
Price / Earnings ratio: 59.3x
EPS (TTM): $1.53
Volume: Loading
52-week high: $69.77
52-week low: $37.31
Dividend yield: 1.32%
Dividend amount (latest): $0.24
EPS vs analyst estimate: +9.3%Q3 FY25 · $1.17 vs $1.07

Source: third-party data provider, as of November 13, 2026

EPS estimate: analyst consensus

Compare with RPRX

Technical indicators

RSI 14: 79.02
MACD 12/26/9: 2.51
EMA 9 of MACD: 2.16
MACD histogram: 0.36
SMA 50: $61.29; Price above SMA 50
EMA 50: $62.45; Price above EMA 50
SMA 200: $54.34; Price above SMA 200
EMA 200: $53.93; Price above EMA 200

Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.

Analyst ratings

Analyst consensus: Buy

Based on 3 analyst ratings

Strong Sell0

Sell0

Hold0

Buy3

Strong Buy0

Third-party analyst opinion, not a recommendation from Gotrade.

Financials

Performance

Revenue

Net income

Net margin %

2021

2022

2023

2024

2025

3B2B942M0

Debt & Balance Sheet

Total assets

Total liabilities

2021

2022

2023

2024

2025

24B16B8B0

Revenue to Profit

2025

$2.4B

Revenue

$0.0

Cost of revenue

$2.4B

Gross profit

$0.0

Operating expenses

$770.9M

Net income

Earnings

EPS forecast

Actual EPS

$1.17

$1.07

Q3FY25

$1.30

Q4FY25

$1.29

Q1FY26

$1.48

Q2FY26

The market is expecting earnings per share of $1.48 for this quarter. The company has not yet shared when it is announcing earnings.

Source: third-party data provider

About Royalty Pharma

Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. Since our founding in 1996, we have been pioneers in the royalty market, collaborating with innovators from academic institutions and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. We have assembled a portfolio of royalties which entitles us to payments based directly on the top-line sales of many of the industry’s leading therapies.

SectorHealthcare

IndustryBiotechnology

Employees100

CEOMr. Pablo Legorreta

IPO DateJun 16, 2020

HeadquartersNew York, NY

Key Executives

Name	Title	Year Born
Mr. Pablo Legorreta	Founder, Chairman of the Board & CEO	1963
Mr. Christopher Hite	Chairman of Partnering & Investments	1967
Mr. Terrance P. Coyne	Executive VP & CFO	—
Dr. Marshall Jonathan Urist M.D., Ph.D.	Head of Research & Investments	1976
Mr. Greg Butz	Executive Vice President of Partnering & Investments	—
Mr. Eric Cornelius Schneider	Senior VP & Chief Technology Officer	—
Dr. James Folmar Reddoch Ph.D.	Executive VP of Investments & Chief Scientific Officer	1970
Mr. George Grofik C.F.A., CPA	Senior VP and Head of Investor Relations & Communications	—
Mr. Arthur Richard McGivern J.D.	Executive VP of Investment & Chief Legal Officer	1975
Ms. Molly Sawaya	Executive VP & Head of Human Capital	—

Seasonality

Monthly price change (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2021											-4.6	+2.8
2022	+1.8	-3.2	+0.4	+8.2	-2.9	+3.3	+1.8	-2.2	-4.3	+5.3	+4.1	-10.3
2023	-0.5	-7.8	+1.2	-2.0	-7.3	-7.3	+2.2	-3.5	-10.3	+0.2	-0.6	+2.7
2024	+0.4	+5.8	+1.5	-7.4	-2.4	-1.8	+7.6	+1.9	-2.0	-4.9	-1.6	-3.5
2025	+22.5	+7.4	-8.1	+5.3	+1.2	+8.3	+2.6	-3.0	-2.5	+3.4	+7.3	-3.2
2026	+7.3	+9.1	+1.1	+3.3	+12.7	+1.6	+4.8	+7.4	-6.4	+16.6	+5.2

Stocks in the same sector

Vertex Pharmaceuticals

ABEO

Abeona Therapeutics Inc.

FAQ

Buying Royalty Pharma (RPRX) stock is now easy and instant through the Gotrade app.

Download the Gotrade app from the App Store or Google Play.
Create an account and verify your identity.
Make a deposit.
Search for the code "RPRX", then tap "Trade".
Tap the "Buy" button.
Enter the amount you want to buy. You have two options:
1. Buy RPRX by number of shares.
2. Buy fractional shares in dollars, starting from $1.
Swipe up to confirm your order, and you're done!

On Gotrade, you don't have to buy a full share. With fractional shares, you can start investing in Royalty Pharma from just $1. A small budget shouldn't stop you from building a US stock portfolio.

Yes, Royalty Pharma regularly pays dividends to shareholders. Currently, the estimated dividend yield for RPRX is around 1.32% per year. On Gotrade, cash dividends will be automatically credited to your account balance (after taxes).

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

You can place an order any time. It goes through when the US market (NYSE/NASDAQ) opens: 9:30 AM to 4:00 PM New York time, Monday to Friday. Pre-market and after-hours trading are open too.

The market is closed on US public holidays. The Gotrade app shows whether the market is open.

There's no single perfect answer, but common approaches include:

Compare valuation (e.g., P/E, P/S) against historical averages or competitors.
Review revenue and earnings growth.
Check margins and cash flow.
Evaluate business outlook and the company's position within its industry.

You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Trade Faster. Easier. Smarter.

#ReadyGoTrade

Welcome Reward up to $1,888

Create an account and trade US stocks on Gotrade

Download app

*Terms & conditions apply

Royalty Pharma (RPRX) Stock

Key stats

Compare with RPRX

Recent news

Unveiling Royalty Pharma (RPRX) Q3 Outlook: Wall Street Estimates for Key Metrics

Unveiling Royalty Pharma (RPRX) Q3 Outlook: Wall Street Estimates for Key Metrics

Should You Buy Royalty Pharma Stock Before Nov. 4?

Should You Buy Royalty Pharma Stock Before Nov. 4?

Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

3 Reasons Royalty Pharma Is a Dividend Stock You Never Have to Sell

3 Reasons Royalty Pharma Is a Dividend Stock You Never Have to Sell

Technical indicators

Analyst ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

Unveiling Royalty Pharma (RPRX) Q3 Outlook: Wall Street Estimates for Key Metrics

Unveiling Royalty Pharma (RPRX) Q3 Outlook: Wall Street Estimates for Key Metrics

Should You Buy Royalty Pharma Stock Before Nov. 4?

Should You Buy Royalty Pharma Stock Before Nov. 4?

Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

3 Reasons Royalty Pharma Is a Dividend Stock You Never Have to Sell

3 Reasons Royalty Pharma Is a Dividend Stock You Never Have to Sell

Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy?

Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy?

Royalty Pharma Eyes AI, China Growth While Navigating Biopharma Policy Shifts

Royalty Pharma Eyes AI, China Growth While Navigating Biopharma Policy Shifts

Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines?

Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines?

Watch These 2 Energy Stocks — S&P 500 Addition Could Come Before Quarter's End

Watch These 2 Energy Stocks — S&P 500 Addition Could Come Before Quarter's End

MRK, RPRX Stocks Hit 52-Week Highs – What Drove Today’s Gains?

MRK, RPRX Stocks Hit 52-Week Highs – What Drove Today’s Gains?

Royalty Pharma (RPRX) Crossed Above the 20-Day Moving Average: What That Means for Investors

Royalty Pharma (RPRX) Crossed Above the 20-Day Moving Average: What That Means for Investors

About Royalty Pharma

Key Executives

Fundamentals

Valuation

Profitability

Trading

Dividend

Technical indicators

Analyst views

Seasonality

Corporate actions

Upcoming

Past

Compare stocks

Market cap

Price / Earnings ratio

Price / Sales ratio

Dividend yield

Average volume

Earnings per share

Stocks in the same sector

FAQ

Trade Faster. Easier. Smarter.

#ReadyGoTrade